IRIX - Pangali PEG IRIDEX Corporation

The change in the PEG ratio demonstrates the dynamics of market value relative to earnings, with the current figure standing at 0.00. IRIDEX Corporation is based in the US, supplying equipment for the treatment of diabetic retinopathy and glaucoma worldwide. A stable workforce is maintained by a strong brand and comprehensive benefits package, while business maturity is evidenced by the implementation of advanced MicroPulse systems to improve the quality of ophthalmological surgeries.

IRIDEX Corporation (IRIX) technological leadership in the laser ophthalmic surgery segment is reflected in the dynamics of the PEG ratio and EPS growth. This metric adjusts the market multiple for earnings growth rates, determining the cost of each unit of business expansion. For the patent-protected MicroPulse systems, this allows for an assessment of price fairness relative to the speed of market penetration. A value below one signals that the asset is undervalued. Investors should utilize this filter to identify undervalued "rockets."